Rolake Neba

Dr. Rolake Neba

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2024 in Journal of Multimorbidity and Comorbidity
Verified
Journal Article
Open access
RNRolake Neba
Rolake Neba
HWHao Wang
Hao Wang
MKMisozi Kolala
Misozi Kolala
USUsha Sambamoorthi
Usha Sambamoorthi
Background: Multimorbidity, defined as the concurrent presence of ≥ 2 chronic conditions, and chronic pain (i.e., pain lasting ≥3 months) often co-exist. Multimodal pain management that includes non-pharmacologic treatment and non-opioid therapy is recommended to prevent serious risks associated with opioids. Purpose: Estimate the prevalence of types of pain treatment and analyze their associations with multimorbidity using a nationally representative survey in the United States (US). Methods: Data was collected from the 2020 National Health Interview Survey among adults with chronic pain and chronic conditions (N= 12,028). Chronic pain management was grouped into four categories: opioid therapy; non-opioid multimodal pain treatment ; pain treatment with monotherapy; and no pain treatment. Chi-square tests and multivariable multinomial logistic regressions were used to analyze the association of multimorbidity with types of pain treatment after controlling for age, sex, social determinants of health (SDoH), and lifestyle characteristics. Results: Among NHIS respondents, 68% had multimorbidity. In adjusted multinomial logistic regressions with “pain management with monotherapy” as the reference group, those with multimorbidity were more likely to utilize opioids (AOR=1.63, 95% CI=1.23, 2.17). Those with severe pain were also more likely to use opioid therapy (AOR=19.36, 95% CI=13.35, 28.06) than those with little pain. Those with low income and education were less likely to have multimodal pain management without opioids. Conclusion: Seven in 10 adults had multimorbidity. Those with multimorbidity reported severe pain and relied on opioids for pain control. Regardless of multimorbidity status, SDoH was associated with types of chronic pain management.

27 October 2025 in Healthcare
Verified
Journal Article
Open access
PDF file
RNRolake Neba
Rolake Neba
LPLakshmi Sraddha Pedaprolu
Lakshmi Sraddha Pedaprolu
BNBryan Neba
Bryan Neba
Usha SambamoorthiUsha Sambamoorthi
Usha Sambamoorthi
Background: Long COVID can lead to a considerable economic burden because of ongoing care for persistent symptoms such as fatigue, dyspnea, or cognitive dysfunction. However, systematic research quantifying healthcare expenditures associated with long COVID remains limited. Objective: This study estimated the excess total, payer, and out-of-pocket healthcare expenditures associated with long COVID among adults in the United States (US). Methods: This was a cross-sectional analysis on adults ≥18 years using 2022 Medical Expenditure Panel Survey (MEPS) data (N = 17,119; representing approximately 254 million adults). Economic burden was measured with (1) total, (2) payer, and (3) out-of-pocket expenditures by individuals and their families. Generalized linear models (GLMs) with gamma distribution and log link were utilized to estimate excess expenditures associated with long COVID after adjusting for age, sex, race and ethnicity, social determinants of health, health status, and lifestyle factors. Results: Overall, 7.0% of the population reported long COVID. Adults with long COVID exhibited higher total (USD 11,305 vs. USD 7162) and payer (USD 9983 vs. USD 6097) expenditures compared to those with no COVID. In a fully adjusted analysis, long COVID was associated with an excess of USD 4098 in total healthcare expenditures and USD 3705 in payer expenditures. We did not observe significant differences in out-of-pocket expenditures between those with long COVID and no COVID. Conclusions: Adults with long COVID had 1.5 times higher total healthcare costs compared to those without COVID. This study highlights the need for comprehensive strategies and policies to reduce the economic burden associated with long COVID.

3 May 2023 in Global Advances in Integrative Medicine and Health
Verified
Journal Article
Open access
RNRolake Neba
Rolake Neba
MWMayela Warner
Mayela Warner
SMSydney E. Manning
Sydney E. Manning
RWR. Constance Wiener
R. Constance Wiener
USUsha Sambamoorthi
Usha Sambamoorthi
Background: Whole health is a holistic approach encompassing integrative medicine, emotional, and spiritual health and is critical to improving health outcomes among individuals with multimorbidity. Objective: To examine the prevalence of Whole Health activities and the association of multimorbidity and Whole Health activities using nationally representative datasets. Methods: As no single dataset has information on Whole Health self-care activities, data from the 2017 National Health Interview Survey (n = 25 134) was used to measure participants’ mind-body therapy usage, sleep, mental health, and physical activity. We used the 2017 Behavioral Risk Factor Surveillance System (n = 347 029) to assess regular vegetable and/or fruit consumption. Results: A significantly lower percentage of adults with multimorbidity had adequate sleep (58.2%vs.67.1%), no psychological distress (71.8%vs.82.1%), adequate physical activity (48.2%vs.62.1%), and regular vegetable and/or fruit consumption (54.2%vs.56.6%) compared to those without multimorbidity. Although lower percentages of adults with multimorbidity utilized mind-body therapies (22.9%vs.25.2%), the association was reversed when adjusted for socioeconomic factors. In the fully adjusted models, adults with multimorbidity were more likely to use mind-body therapies (AOR = 1.19, 95%CI = 1.09, 1.31). Furthermore, when adjusting for other independent variables, the associations of multimorbidity with sleep, psychological distress, and diet were exacerbated, and the association of multimorbidity with physical activity was attenuated. Conclusion: Adults with multimorbidity were less likely to engage in most of the Whole Health activities except mind-body therapies compared to the no multimorbidity group. Findings suggest that adjustment for other factors such as age and socioeconomic status changed the magnitude and direction of the association of multimorbidity with Whole Health activities.

25 March 2025 in COVID
Verified
Journal Article
Open access
PDF file
RNRolake Neba
Rolake Neba
IMIman Mohamed
Iman Mohamed
TITheodora Iwudibia
Theodora Iwudibia
JPJahnavi Pinnamraju
Jahnavi Pinnamraju
Usha SambamoorthiUsha Sambamoorthi
Usha Sambamoorthi
Long COVID is characterized by persistent symptoms following the resolution of an acute COVID-19 infection. Long COVID may affect cognition due to possible ischemia, neuro-inflammation, and hypoxia related to COVID-19. The purpose of this study was to analyze the association of long COVID with severe cognitive limitations. Utilizing data from the 20 September–2 October 2023 Census Household Pulse Survey among adults, COVID status was categorized as: (1) long COVID, (2) COVID-19, or (3) no COVID. The cognitive limitations were abstracted from the Washington Group Short Set on Functioning, as follows: No difficulty; Some difficulty; A lot of difficulty; and Cannot do at all; we combined “a lot of difficulty” or “unable to do” under the category “severe cognitive limitation”. Rao–Scott Chi-square tests and multivariable multinomial logistic regressions that accounted for replicate weights were used to analyze the adjusted association of long COVID with cognitive limitations. Overall, 15.1% had long COVID. A higher percentage of adults with long COVID (13.1% vs. 4.1%) reported severe cognitive limitations compared to no COVID (p < 0.001). In a fully adjusted logistic regression model, adults with long COVID were more likely to report at least a lot of difficulty in cognition (aOR = 1.64 95% CI = 1.38, 1.96) compared to no COVID.

11 September 2026 in Healthcare
Verified
Journal Article
Open access
PDF file
MNMichelle Ndiulor
Michelle Ndiulor
HWHao Wang
Hao Wang
RNRolake Neba
Rolake Neba
RRRafia Rasu
Rafia Rasu
BZBo Zhou
Bo Zhou
Usha SambamoorthiUsha Sambamoorthi
Usha Sambamoorthi
Background/Objectives: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly prescribed for type 2 diabetes mellitus (T2DM). However, its mental health safety profile in routine care, particularly among Medicaid beneficiaries, remains uncertain. We aim to examine the association between glucagon-like peptide-1 receptor agonist (GLP-1 RA) use and newly documented depression diagnosis among adults with type 2 diabetes mellitus (T2DM) enrolled in Medicaid. Methods: We conducted a retrospective longitudinal cohort study using the 2022–2023 Merative™ MarketScan® Multi-State Medicaid Database. Adults aged 18–64 years with T2DM, continuous Medicaid enrollment, and no documented depression during the 2022 baseline period were included. Baseline GLP-1 RA use was assessed in 2022, and newly diagnosed depression was identified in 2023. Associations were estimated using multivariable logistic regression, inverse probability weighting (IPW), and a doubly robust estimator. Results: Among 74,760 eligible adults, 14,953 (20.0%) were GLP-1 RA users. Incident depression occurred in 12.9% of users and 11.1% of non-users (absolute difference, 1.8 percentage points; p < 0.001). GLP-1 RA use was associated with higher odds of newly documented depression diagnosis in multivariable analysis (adjusted OR 1.10, 95% CI 1.04–1.16), IPW analysis (OR 1.09, 95% CI 1.03–1.15), and doubly robust analysis (OR 1.09, 95% CI 1.03–1.15). Conclusions: Baseline GLP-1 RA use was associated with modestly higher odds of a newly documented depression diagnosis during the subsequent year. Prospective studies are needed to determine whether this association is causal.

10 July 2026 in Annals of Hematology
Verified
Journal Article
Open access
KRKayla Riley
Kayla Riley
RNRolake Neba
Rolake Neba
AAAdenike Atanda
Adenike Atanda
Pain is a debilitating complication of sickle cell disease (SCD), driven by recurrent vaso-occlusive crises and chronic pain syndromes involving central sensitization and neuropathic mechanisms. Although opioid medications remain first-line therapy for acute pain, there are limitations that highlight the need for effective adjunctive approaches. Available data support non-opioid pharmacologic therapies including acetaminophen and nonsteroidal anti-inflammatory drugs as components of multimodal analgesia, with emerging evidence for therapies targeting neuropathic and centralized pain. Non-pharmacologic interventions such as cognitive behavioral therapy have also demonstrated potential benefits as adjunctive strategies in SCD pain management. This literature review examines evidence supporting non-opioid pharmacologic and non-pharmacologic therapies for pain management in SCD and is based on structured searches of PubMed, MEDLINE, and Cochrane databases.